Six things move mid-year: the plan’s drug list, the benefit stage you are in, the prior authorization end date, the pharmacy network, your Extra Help status, and the price the manufacturer sets. Only some of them let you switch plans in response. Work out which one moved before deciding anything, because the fix differs completely.
The counter price can change with nothing else changing
Medicare drug plans run three cost stages in a calendar year, and moving between them changes what a person pays without the plan doing anything. In the deductible stage the enrollee pays the full amount until the deductible is met, and in 2026 no plan may set a deductible above $615. In the initial coverage stage the enrollee pays 25 percent coinsurance for covered generic and brand drugs. Once out-of-pocket spending on covered Part D drugs reaches $2,100 in 2026, catastrophic coverage begins and covered drugs cost nothing for the rest of the year.
That is why the same prescription can cost three different amounts in one year at the same pharmacy. The Explanation of Benefits that arrives the month after the pharmacy bills the plan shows which stage applies and what has counted toward the totals. It is the fastest way to answer the question of whether coverage changed or the calendar simply moved.
Drug lists move, and the plan has to tell you
Plans can change their drug lists during the year under guidelines set by Medicare, when therapies change, new products arrive or new information appears. The plan must notify members about changes affecting drugs they are taking. Two quieter shifts also raise cost sharing without a drug leaving the list: coinsurance can rise when the manufacturer raises a price, and a brand can be moved to a higher tier once the plan adds a generic or biosimilar version.
Because plans build their own lists, the coverage question is always specific to one plan in one year. Mounjaro carries a single indication, type 2 diabetes in adults and in pediatric patients from 10 years of age, taken with diet and exercise. Zepbound is the tirzepatide product licensed for weight reduction and maintenance, and for moderate to severe obstructive sleep apnea in adults with obesity. Plans treat those as separate coverage questions, and a mid-year change to one says nothing about the other.
What changed, and when you can respond
| What moved | How you find out | When you can act |
|---|---|---|
| Benefit stage | Explanation of Benefits | No action available, it resets in January |
| Plan drug list | Notice from the plan | Exception now, plan switch at Open Enrollment |
| Prior authorization expired | Refill rejects at the pharmacy | New request through the plan immediately |
| Pharmacy left the network | Claim rejects or price jumps | Switch pharmacies at any time |
| Extra Help status | Letter from Medicare or Social Security | Special Enrollment Period may apply |
| Plan terms for next year | Annual Notice of Change in the fall | October 15 to December 7 |
The expiry nobody diaries
Prior authorizations are granted for a defined period, and the end date sits on the approval letter. Nothing announces its arrival. A refill that went through cleanly in June rejects in July, and the review starts again, frequently asking for updated values or a note on progress. This is one of the most common mid-year interruptions and one of the easiest to prevent with a calendar reminder set a few weeks before the date on the letter.
Extra Help and the windows for switching plans
Extra Help runs on the calendar year in a way that works in the enrollee’s favor. Once qualified, the help continues through December 31 even if income rises mid-year. Medicare updated the 2026 limits to $23,940 in income and $18,090 in resources for an individual, and $32,460 and $36,100 for a married couple, and anyone can reapply when circumstances change. Under Extra Help in 2026 the premium and deductible are zero and covered prescriptions cost no more than $5.10 for a generic or $12.65 for a brand at a participating pharmacy.
Switching plans is more restricted. Open Enrollment runs October 15 to December 7 for coverage beginning January 1. People already in a Medicare Advantage plan get a second window, January 1 to March 31, to move to another Medicare Advantage plan or return to Original Medicare with a separate drug plan. Special Enrollment Periods cover specific life events such as moving, losing other coverage, gaining Medicaid or gaining Extra Help. Outside those, a mid-year formulary change is handled through an exception request rather than by changing insurer.
Two programs with dates of their own
The Medicare Prescription Payment Plan spreads what is owed across the remaining months in capped payments rather than charging it all at the counter. It reduces nothing, but it can be joined mid-year.
CMS also opened a short-term demonstration on July 1, 2026 called the Medicare GLP-1 Bridge, scheduled to run through December 31, 2027, providing certain GLP-1 drugs for weight management at a $50 monthly copay. It does not apply here. CMS excludes anyone with type 2 diabetes on the grounds that their indication belongs with the Part D plan, and the covered products are Foundayo, Wegovy and the Zepbound KwikPen. Its copay sits outside the Part D payment flow, so it does not count toward the out-of-pocket total and Extra Help cannot reduce it. Given the fixed end date, confirm current terms at Medicare.gov.
A separate roster of sellers handles the branded drug rather than a compound. HealthRX and LillyDirect sit among the telehealth and manufacturer channels that publish what FDA-approved Mounjaro costs when it is paid for directly, a figure that runs higher than a compounded plan and, like every off-plan purchase, never reaches the Part D out-of-pocket total.
The cash lane, and what it does to the annual counter
Some people respond to a mid-year change by leaving the plan behind. FormBlends, Ro and Hims and Hers each operate as a physician-supervised GLP-1 provider charging a published monthly rate for compounded tirzepatide or semaglutide after a clinician review. Compounded medicine is not FDA-approved, has not been evaluated for safety, effectiveness or manufacturing quality, and Part D does not cover it. The arithmetic deserves attention before anyone commits: money spent outside the plan does not count toward the deductible or the annual out-of-pocket threshold, so a household that switches to cash in July arrives at December no closer to catastrophic coverage than it was in June. Medicare says the same of discount cards, which are not creditable coverage.
Frequently asked questions
Can a plan drop a drug in the middle of the year?
Yes, within guidelines Medicare sets, and the plan must notify members whose drugs are affected. The response available mid-year is a formulary exception supported by a prescriber statement. Changing plans over it generally waits for Open Enrollment unless a Special Enrollment Period applies.
Why did the price jump in March with no letter from the plan?
Most often the deductible was met or the benefit moved into a new stage, neither of which generates a notice. Coinsurance can also rise when a manufacturer raises the drug’s price. The Explanation of Benefits shows the current stage and what has accumulated, which settles the question quickly.
Does an approved authorization survive a plan switch in January?
No. Approvals belong to the plan that issued them, and a new plan applies its own list and rules from day one. Some plans provide a one-time 30-day transition fill when coverage begins, which buys time while a fresh request is filed. Start that request in December.
Should the drug be rechecked before December 7?
Every year. Plans change lists, tiers and rules annually, and the Annual Notice of Change arrives in the fall for exactly this reason. Running the prescription through the plan finder at Medicare.gov during the window shows which plans in the area cover it and at what estimated yearly cost.
